Contents

Issue 114 • January 2022

In association with

In association with

The challenges of multiple drugs safety reporting

Safety reporting for treatments involving multiple drugs must improve to protect patients from harmful drug-drug interactions

IN DEPTH

Pfizer and Takeda deals put a spotlight on value-based pricing

Comment

How has AI helped in combating the spread of Covid-19?

Briefing

Industry news

Pharma industry briefing

Covid-19 briefing

Comment

How has AI helped in tackling Covid-19?

What does Ireland’s tax hike mean for pharma?

Chinese review designations lag behind US and EU

The benefits of text mining for life sciences

In Depth

Narrow FDA vote on Merck’s molnupiravir bolsters outlook on mAbs

The challenges of multiple drugs safety reporting

Pfizer and Takeda deals put a spotlight on value-based pricing

3D printing in drug manufacturing: unlocking future possibilities

Can drug repurposing uncover better treatments for UTIs?

Lethal injection: can pharma kill the death penalty?

In Data

Data analytics jobs in clinical trials are on the rise

Middle-income countries’ healthcare markets will continue to grow

Industrial automation innovation in pharma rebounds

Markets and indices

Macro-economic data

12/15/2021 12:38:39
  • Home | Improving safety for multiple drug regimes 
  • In this issue
  • Contents
  • Curtis Health Caps
  • Astrix
  • Briefing
  • Industry news
  • The pharma industry briefing
  • Covid-19 executive briefing by GlobalData
  • Owen Mumford Company Insight
  • Owen Mumford
  • Comment
  • Use of AI in the fight against Covid-19 shows mixed results
  • What does Ireland’s tax hike mean for pharma?
  • Chinese review designations lag behind US and EU
  • The business benefits of text mining in life sciences
  • Mettler Toledo
  • HOF Sonderanlagenbau
  • In Depth
  • Narrow FDA panel vote on Merck’s molnupiravir bolsters outlook on mAbs
  • The challenges of multiple drugs safety reporting
  • 3D printing in drug manufacturing: unlocking future possibilities
  • Can drug repurposing uncover better treatments for UTIs?
  • Pfizer and Takeda deals put a spotlight on value-based pricing
  • Lethal injection: can pharma kill the death penalty?
  • Mimotopes Company Insight
  • Mimotopes
  • In Data
  • Middle-income countries’ healthcare sectors to keep rising through to 2024
  • Data analytics hiring levels in clinical trial operations rose in October
  • Industrial automation innovation in pharma rebounded in the last quarter
  • Global markets and indices
  • Macro-economic indicators
  • Macro-economic indicators (page 2)
  • Yearbook
  • SHL Medical
  • Dr. Paul Lohmann Company Insight
  • Dr. Paul Lohmann
  • Novo Nordisk
  • Nipro
  • Events
  • Next issue